Form D · Biotechnology
Concentric Analgesics, Inc.
San Francisco, CA · CIK 0001682398
Offering snapshot reported Dec 16, 2021 · SEC filing
- Reported sold
- $20M Offering amount: $40M
- Investors reported
- 116 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 1, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 16, 2021 | Initial | $20,030,036 | No comparison | 116 | SEC filing |
| May 23, 2019 | Initial | $77,100,822 | No comparison | 144 | SEC filing |
| Nov 13, 2018 | Amendment | $20,000,000 | $13,397,865vs Aug 2, 2018 | 109 | SEC filing |
| Aug 2, 2018 | Initial | $6,602,135 | No comparison | 61 | SEC filing |
| Dec 14, 2017 | Initial | $5,351,896 | No comparison | 79 | SEC filing |
| Dec 7, 2016 | Amendment | $8,356,297 | $1,752,951vs Oct 21, 2016 | 82 | SEC filing |
| Oct 21, 2016 | Amendment | $6,603,346 | $599,998vs Sep 26, 2016 | 65 | SEC filing |
| Sep 26, 2016 | Amendment | $6,003,348 | $24,997vs Aug 17, 2016 | 63 | SEC filing |
| Aug 17, 2016 | Initial | $5,978,351 | No comparison | 62 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-425385
$20 mil new money; $30,036.97 upon the exercise of warrants; $20 mil remaining to be sold upon conditional second tranche
Source: Form D, filed Dec 16, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Frank J. Bellizzi | Director, Executive |
| John F. Donovan | Director, Executive |
| Larry Feinberg | Director |
| Craig Husfeld | Executive |
| Thomas King | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
101 California Street Suite 1210
San Francisco, CA, 94111
San Francisco, CA, 94111